{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:51:13Z","timestamp":1765374673196,"version":"3.46.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Anti-immunoglobulin-like cell adhesion molecule 5 (IgLON5) disease is a rare autoimmune encephalitis that shares clinical features with progressive supranuclear palsy (PSP), complicating differential diagnosis. Here, we sought to investigate whether PET imaging using [\n                      <jats:sup>18<\/jats:sup>\n                      F\n                      <jats:underline>]<\/jats:underline>\n                      Florzolotau and [\n                      <jats:sup>18<\/jats:sup>\n                      F\n                      <jats:underline>]<\/jats:underline>\n                      FDG could distinguish these disorders through characteristic patterns of tau deposition and cerebral glucose metabolism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Eleven patients with serologically confirmed anti-IgLON5 disease, 20 patients with PSP diagnosed according to the 2017 Movement Disorder Society criteria, and 40 age-matched and sex-matched healthy controls were enrolled. Participants underwent [\n                      <jats:sup>18<\/jats:sup>\n                      <jats:underline>F]<\/jats:underline>\n                      Florzolotau and\/or [\n                      <jats:sup>18<\/jats:sup>\n                      <jats:underline>F]<\/jats:underline>\n                      FDG PET imaging. Visual interpretation and semiquantitative analyses, including voxel-based and region-of-interest approaches, were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Anti-IgLON5 patients showed significant [\n                      <jats:sup>18<\/jats:sup>\n                      F]Florzolotau binding in subcortical regions, including the midbrain, pons, caudate, putamen, and thalamus, along with additional involvement of the parietal lobe and cerebellum. PSP patients demonstrated overlapping [\n                      <jats:sup>18<\/jats:sup>\n                      F]Florzolotau uptake in the caudate, putamen, thalamus, midbrain, and pons, but with distinct additional binding in the frontal lobe. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET revealed contrasting metabolic profiles: anti-IgLON5 disease was associated with diffuse cortical hypometabolism, whereas PSP showed regionally restricted hypometabolism, mainly in the frontal lobe, caudate, putamen, midbrain, and pons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      We identified distinct PET signatures that can reliably differentiate anti-IgLON5 disease from PSP. The complementary application of [\n                      <jats:sup>18<\/jats:sup>\n                      F\n                      <jats:underline>]<\/jats:underline>\n                      Florzolotau and [\n                      <jats:sup>18<\/jats:sup>\n                      F\n                      <jats:underline>]<\/jats:underline>\n                      FDG PET imaging may provide valuable biomarkers for differential diagnosis in clinically ambiguous cases, potentially enabling timely immunotherapeutic interventions for patients with imaging patterns suggestive of anti-IgLON5 disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006155","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:00:20Z","timestamp":1765328420000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative [18F]Florzolotau and [18F]FDG PET Imaging Patterns in Anti-IgLON5 Disease and Progressive Supranuclear Palsy"],"prefix":"10.1097","volume":"51","author":[{"given":"Chenhao","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8765-0799","authenticated-orcid":false,"given":"Tianhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Engineering Research Center of Radiographic Techniques and Equipment, Institute of High Energy Physics, Chinese Academy of Sciences"},{"name":"School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qijun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoxia","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chen","family":"Yen","sequence":"additional","affiliation":[{"name":"APRINOIA Therapeutics Co, Ltd, Suzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhi","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-9110","authenticated-orcid":false,"given":"Siyuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"R1-20251210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"R2-20251210","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"R3-20251210","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and characterization of movement disorders in anti-IgLON5 disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"R4-20251210","doi-asserted-by":"crossref","first-page":"1756286421998906","DOI":"10.1177\/1756286421998906","article-title":"Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression","volume":"14","author":"Banks","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"R5-20251210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R6-20251210","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00401-023-02625-6","article-title":"Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease","volume":"146","author":"Berger-Sieczkowski","year":"2023","journal-title":"Acta Neuropathol"},{"key":"R7-20251210","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1212\/NXI.0000000000000651","article-title":"Anti-IGLON5 disease: a new case without neuropathologic evidence of brainstem tauopathy","volume":"7","author":"Erro","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R8-20251210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gr\u00fcter","year":"2023","journal-title":"Brain"},{"key":"R9-20251210","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R10-20251210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00415-024-12874-4","article-title":"Patterns of tau pathology in patients with anti-IgLON5 disease visualized by Florzolotau (18F) PET","volume":"272","author":"Fan","year":"2025","journal-title":"J Neurol"},{"key":"R11-20251210","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"R12-20251210","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00259-022-05752-6","article-title":"Unified spatial normalization method of brain PET images using adaptive probabilistic brain atlas","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20251210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies","volume":"109","author":"Tagai","year":"2021","journal-title":"Neuron"},{"key":"R14-20251210","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-022-06104-0","article-title":"(18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy","volume":"50","author":"Liu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20251210","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1053-8119(03)00169-1","article-title":"An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets","volume":"19","author":"Maldjian","year":"2003","journal-title":"NeuroImage"},{"key":"R16-20251210","doi-asserted-by":"crossref","first-page":"116189","DOI":"10.1016\/j.neuroimage.2019.116189","article-title":"Automated anatomical labelling atlas 3","volume":"206","author":"Rolls","year":"2020","journal-title":"NeuroImage"},{"key":"R17-20251210","doi-asserted-by":"crossref","first-page":"e2325","DOI":"10.1212\/WNL.0000000000207870","article-title":"In vivo measurement of tau depositions in anti-IgLON5 disease using [18F]PI-2620 PET","volume":"101","author":"Theis","year":"2023","journal-title":"Neurology"},{"key":"R18-20251210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40478-018-0552-y","article-title":"Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain","volume":"6","author":"Kovacs","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"R19-20251210","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Clinical utility of (18) F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy","volume":"36","author":"Li","year":"2021","journal-title":"Mov Disord"},{"key":"R20-20251210","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain"},{"key":"R21-20251210","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol"},{"key":"R22-20251210","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"(18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann Neurol"},{"key":"R23-20251210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol"},{"key":"R24-20251210","doi-asserted-by":"crossref","first-page":"e200353","DOI":"10.1212\/NXI.0000000000200353","article-title":"Anti-IgLON5 disease 10 years later: what we know and what we do not know","volume":"12","author":"Graus","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R25-20251210","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1007\/s00415-024-12350-z","article-title":"Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants","volume":"271","author":"Black","year":"2024","journal-title":"J Neurol"},{"key":"R26-20251210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jocn.2020.06.008","article-title":"Clinical, MRI and 18F-FDG-PET\/CT analysis of progressive supranuclear palsy","volume":"80","author":"Zhao","year":"2020","journal-title":"J Clin Neurosci"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:01:18Z","timestamp":1765371678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006155","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-07-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}